Investors

2016 Press Releases

Webcast ImageWebcast
Regulatory Update for Voxelotor (Replay)
12/03/18 at 8:30 a.m. ET
Regulatory Update for Voxelotor
Monday, December 3, 2018 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Global Blood Therapeutics Inc at the American Society of Hematology (ASH) 2018 Annual Meeting (Replay)
12/03/18 at 3:00 p.m. ET
Global Blood Therapeutics Inc at the American Society of Hematology (ASH) 2018 Annual Meeting
3:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Supporting Materials
Download Event Supporting Material ASH IR Event Presentation Slides
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/16/16Global Blood Therapeutics Added to NASDAQ Biotechnology Index
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI). GBT’s addition to the NBI will become effective upon market open on Monday, December 19, 2016. The NASDAQ Biotechnology Index, which is re-ranked annually, is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or ... 
Printer Friendly Version
12/05/16Global Blood Therapeutics Announces New Details on its Novel Patient Reported Outcomes (PRO) Tool to be used in Phase 3 HOPE Study
-- PRO designed to establish clinical benefit – -- First time a PRO to be used as a secondary clinical endpoint in a SCD registrational study -- --Company to Host Webcast Today at 12:15 p.m. PT to Discuss ASH Data Presentations — SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the methodology used to develop the Patient Reported Outcome (PRO) tool that will be used as a secondary clinical endpoint in th... 
Printer Friendly Version
12/04/16Global Blood Therapeutics Announces New Long-Term Clinical Data from Ongoing Phase 1/2 Trial of GBT440 in Sickle Cell Disease at ASH
--Results Showed GBT440 Treatment Led to Rapid, Significant, Profound and Durable Reduction in Hemolysis and Sickled Cells in All Patients Treated for Up to Six Months-- --Company to Host Webcast Tomorrow at 12:15 p.m. PT to Discuss Data-- SOUTH SAN FRANCISCO, Calif., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of results from its ongoing Phase 1/2 GBT440-001 study that further support the safety and efficacy profile o... 
Printer Friendly Version
11/30/16Global Blood Therapeutics Announces Upcoming Investor Webcast to Review GBT440 Data Being Presented at ASH that Support Sickle Cell Disease Program
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will host an investor webcast on Monday, December 5, 2016, at 12:15 p.m. PT/3:15 p.m. ET, to review new data being presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Conference in San Diego that support its GBT440 program in sickle cell disease (SCD). The investor event will feature members of GBT’s management team an... 
Printer Friendly Version
11/30/16Global Blood Therapeutics Announces GBT440 Granted Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that the European Commission (EC), acting on a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has designated GBT440 as an orphan medicinal product for the treatment of sickle cell disease (SCD). "Receiving orphan designation from the EC marks a significant milestone both for the SCD co... 
Printer Friendly Version
11/28/16Global Blood Therapeutics Announces Initiation of Phase 2a Trial of GBT440 in Idiopathic Pulmonary Fibrosis (IPF)
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced enrollment of the first patient in ZEPHYR, a Phase 2a clinical trial evaluating the safety and efficacy of GBT440 for the treatment of hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest. Hypoxemia (abnormally low levels of oxygen in the blood) is a common finding in IPF, is the underlying cause for patients’ sym... 
Printer Friendly Version
11/09/16Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today reported business progress and financial results for the third quarter ended September 30, 2016. “We continue to make important progress across our GBT440 development programs and are particularly excited to have reached agreement with... 
Printer Friendly Version
11/03/16Global Blood Therapeutics Announces Upcoming Presentation of Data Supporting Sickle Cell Disease Program at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Conference
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that new data supporting its GBT440 program in sickle cell disease (SCD) will be presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego. The poster presentations will include addi... 
Printer Friendly Version
10/24/16Global Blood Therapeutics Announces Pivotal Study for GBT440 in Sickle Cell Disease with Primary Hemoglobin Endpoint
HOPE – A Phase 3 Clinical Trial to Initiate in December Company to Host Conference Call and Webcast Today at 1:30 p.m. PT/ 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that it has reached agreement with the U. S. Food and Drug Administration (FDA) regard... 
Printer Friendly Version
10/12/16Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the expansion of its management team with the appointment of Tricia Suvari as chief legal officer. “Tricia brings a wealth of experience managing the complex legal and business situations that arise in rapidly growing biopha... 
Printer Friendly Version
10/07/16Global Blood Therapeutics Presents GBT440 Data that Continue to Support Durability, Safety and Mechanism of Action in Sickle Cell Disease
Data Presented at 10th Anniversary Conference of Academy for Sickle Cell and Thalassemia (ASCAT) SOUTH SAN FRANCISCO, Calif., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that an encore presentation of the GBT440-001 study data supporting the durability, safety and mechanism of action of GBT440 in s... 
Printer Friendly Version
09/14/16Global Blood Therapeutics Announces Publication of Preclinical Results Supporting GBT440 Program for Hypoxemic Pulmonary Disorders
Data Published in Physiological Reports Highlight the Potential of GBT440 to Improve Hypoxemia and Delay Pulmonary Fibrosis Progression SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced publication of preclinical data supporting the development of GBT440 for the treatment of ... 
Printer Friendly Version
09/06/16Global Blood Therapeutics Joins Sickle Cell Disease (SCD) Coalition in Support of SCD Community with Goal to Improve Treatment and Care
Coalition Report, ‘State of Sickle Cell Disease: 2016’ Uncovers Unmet Needs in SCD and Provides Strategies to Spur Positive Change SOUTH SAN FRANCISCO, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that in connection with Sickle Cell Disease (SCD) Awareness Month, the company has joined the S... 
Printer Friendly Version
08/31/16Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that its president and chief executive officer, Ted W. Love, M.D. will participate in two upcoming investor conferences. Following are details for each presentation: Wells Fargo Securities Healthcare Conference Date/T... 
Printer Friendly Version
08/10/16Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today reported business progress and financial results for the second quarter ended June 30, 2016. “We made important progress across our GBT440 development programs and strengthened our balance sheet with the completion of our financing in ... 
Printer Friendly Version
08/09/16Global Blood Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that its president and chief executive officer, Ted W. Love, M.D. will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16 at 1:20 p.m. Eastern Time.  The presentation will be webcast live and available... 
Printer Friendly Version
07/08/16Global Blood Therapeutics Announces Publication of Preclinical GBT440 Results in British Journal of Haematology that Support Sickle Cell Disease (SCD) Program
Data Suggest the Potential of GBT440 to Reduce Sickling, Extend the Circulating Half-Life of Red Blood Cells and Decrease Excessive Erythropoiesis in SCD SOUTH SAN FRANCISCO, Calif., July 8, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced publication of preclinical GBT440 results in sickle cell disease (SCD) in th... 
Printer Friendly Version
06/29/16Global Blood Therapeutics Announces Initiation of Phase 2a Study of GBT440 in Adolescents with Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., June 29, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced it has initiated a Phase 2a study of GBT440 in adolescents with sickle cell disease (SCD). GBT is developing GBT440 as a potential disease-modifying therapy for SCD. "We are pleased to initiate our Phase 2a study of GBT440 in ado... 
Printer Friendly Version
06/24/16Global Blood Therapeutics Announces Closing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 24, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the closing of its previously announced underwritten public offering of 6,400,000 shares of common stock, at the public offering price of $18.75 per share. All of the shares in the offering were offered by GBT. GBT estimates net pro... 
Printer Friendly Version
06/20/16Global Blood Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 20, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock at a public offering price of $18.75 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up ... 
Printer Friendly Version
06/20/16Global Blood Therapeutics Announces Initiation of Phase 2a Study of GBT440 in Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., June 20, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced it has initiated a Phase 2a study of GBT440, a hemoglobin modifier, in adults with idiopathic pulmonary fibrosis (IPF) and hypoxemia. Hypoxemia (abnormally low levels of oxygen in the blood) can lead to tissue hypoxia ... 
Printer Friendly Version
06/20/16Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 20, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All shares of common stock will be offered by GBT. In addition, GBT expects to grant the underwriters a 30-day option to purchase u... 
Printer Friendly Version
06/10/16Global Blood Therapeutics Announces New Clinical Data that Continue to Support Safety and Efficacy Profile of GBT440 as a Potentially Disease-Modifying Therapy for Sickle Cell Disease
90-Day Data Show Sustained Treatment Response and Support Company's Plan to Initiate Pivotal Trial This Year Results Presented at European Hematology Association's (EHA) 21st Congress Company to Host Webcast Today at 1:30 p.m. CEST/7:30 a.m. ET to Discuss Data SOUTH SAN FRANCISCO, Calif., June 10, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with sig... 
Printer Friendly Version
06/02/16Global Blood Therapeutics to Host Investor Event on Friday, June 10 to Review GBT440 Data in Sickle Cell Disease Being Presented at the European Hematology Association's 21st Congress
SOUTH SAN FRANCISCO, Calif., June 2, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that it will host an investor webcast on Friday, June 10, 2016, at 1:30 p.m. CEST/7:30 a.m. ET, during which members of GBT's management team and distinguished experts Dr. H. Franklin Bunn of Harvard Medical School and Brigham and Wo... 
Printer Friendly Version
05/19/16Global Blood Therapeutics Announces Presentation of New GBT440 Data in Sickle Cell Disease at the European Hematology Association's 21st Congress
-- Presentations to Include Additional and Longer-Term Data from Ongoing Phase 1/2 Trial -- -- Company to Host Investor Webcast to Review the Data on Friday, June 10 -- SOUTH SAN FRANCISCO, Calif., May 19, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that new GBT440 data will be presented in a poster ... 
Printer Friendly Version
05/18/16Global Blood Therapeutics to Present at the UBS 2016 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 18, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that its chief executive officer, Ted W. Love, M.D. will present a corporate update at the UBS 2016 Global Healthcare Conference on Tuesday, May 24 at 1:30 p.m. Eastern Time.   The presentation will be webcast live and available f... 
Printer Friendly Version
05/12/16Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., May 12, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today reported business progress and financial results for the first quarter ended March 31, 2016. "We began 2016 by expanding our management team and continuing to build clinical evidence for our lead program, GBT440 for the treatment of sickle... 
Printer Friendly Version
04/04/16Global Blood Therapeutics Announces Appointment of Jeffrey Farrow as CFO
SOUTH SAN FRANCISCO, Calif., April 4, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the expansion of its management team with the appointment of Jeffrey Farrow as chief financial officer (CFO). "Jeff's unique skill sets will be instrumental to GBT as we rapidly advance both GBT440 for the treatment of sickle ce... 
Printer Friendly Version
03/29/16Global Blood Therapeutics Reports Recent Business Progress and Provides Fourth Quarter and Year-End 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., March 29, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today reported business progress and financial results for the fourth quarter and year ended December 31, 2015. "In 2015, we successfully transformed GBT into a public company, while demonstrating clinical proof of concept for our lead program,... 
Printer Friendly Version
02/29/16Global Blood Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that its chief executive officer, Ted W. Love, M.D., will present a corporate update at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, at 4:40 p.m. Eastern Time at the Marriot Copley Place in Bosto... 
Printer Friendly Version
02/08/16Global Blood Therapeutics Announces Changes to Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the appointment of Mike Bonney, partner at Third Rock Ventures, and Glenn Pierce, M.D., Ph.D., formerly chief medical officer at Biogen, to its Board of Directors.  The company also announced that Kevin Starr, partner at Third ... 
Printer Friendly Version
01/06/16Global Blood Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that its chief executive officer, Ted W. Love, M.D., will present a corporate update at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, at 4 p.m. Pacific Time at the Westin St. Francis Hotel in San F... 
Printer Friendly Version
01/04/16Global Blood Therapeutics Appoints Scott Morrison to Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the appointment of Scott Morrison, who brings 35 years of financial experience helping life sciences companies excel from start-up, through initial product launch, to global expansion. “Scott Morrison is a well-respected ind... 
Printer Friendly Version